The prevalence of diabetes is quickly growing in the UK, meaning that a higher share of the NHS budget is devoted to diabetes treatment: 40% of these treatment costs come from treating diabetes-related complications. Precision medicine is an approach to medicine that uses a patient's specific genetic and lifestyle information to tailor treatment plans and has shown positive results when implemented for patients with diabetes. MyWay Intelligence Quotient (MWIQ) is an online platform with predictive models that can determine responses to specific pharmacological treatments, diagnosis of diabetes subtypes, and risk of developing certain complications. The goal of the study is to primarily identify and mitigate any risks associated with the platform, and secondly assess the clinical performance of MWIQ (defined through clinical applicability, clinical impact, and clinical usability). Five practices in the Manchester area agreed to take part in the study. Recruitment started in August 2024, and live testing started in March 2025. A maximum of 10 clinician participants (up to 2 from each location) were recruited to provide feedback on how well MWIQ is integrated into the clinical workflow and how well it performs; clinician participants are qualified healthcare professionals and include those who are part of a multidisciplinary team of GPs, specialist registered nurses, and advanced nurse practicioners that interact with diabetes patients regularly. Four validator participants were also recruited to monitor the patient data for any safety concerns. Diabetic patients attending the participating locations were notified of the study and had the option to opt out. Quantitative data will be taken from the server and then pseudonymized; this data will outline the main traits of the diabetic population served by the area. Quantitative data will include diabetes type, investigations such as genetic testing, HbA1c to measure average blood sugar, blood pressure, body mass index, cholesterol, and foot risk score. Time spent on the platform and questionnares for patients to comment on ease of use of the platform/any concerns they may have (e.g. whether the medication recommendation is what they expected) will also be assessed. Qualitative data will come from regularly-occurring interviews throughout the study, each semistructured and 30-45 minutes long, where clinician participants will be able to freely discuss what features of the platform work well and which don't, how easy it is to the use platform and intergrate it into the day-to-day clinical activities, etc. Qualitative data can also come from free-text sections on the questionnaires. As this publication is a study protocol, there are no results to report on as of yet. However, analysis will be done as follows: Run charts will be used to record usability and safety issues (as stated in the questionnaires) and will be reviewed weekly; the content of these charts will be used by the technical teams to improve the platform. The qualitative data will be analyzed in NVivo software to find common themes and patterns in what the clinician participants have said about using MWIQ. A statistical analysis will be done on the quantitative data, which will then be triangulated with the qualitative data for more robust analysis. The researchers expect that the feedback from the clinician participants and those patients who filled out the questionnaire(s) will overall lead to improvements in the MWIQ platform.